Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.55 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.51 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 7/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586177 | 1.00 | TRPA1 (0.55) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL14631813 | 0.86 | MAP2K4 (0.56) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| Tert-Butyl Formate SCHEMBL27811577 | 0.85 | GSK3B (0.44) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL14738709 | 0.82 | KIF11 (0.46) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL2662677 | 0.80 | TRPA1 (0.56) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL26124043 | 0.79 | PRKAA1 (0.41) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL25279396 | 0.79 | TRPA1 (0.55) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL30481233 | 0.79 | TRPA1 (0.55) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL13122227 | 0.79 | TRPA1 (0.55) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 | |
| SCHEMBL10220256 | 0.76 | KIF11 (0.56) | TRPA1MAP2K4MAPK1MAPK6MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117582436-A | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-116836173-B | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116836173-A | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| CN-104024258-B | Pyrrolopyrazine kinase inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-7994202-B2 | Bicyclic nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| CN-102089302-A | Nitrogenated bicyclic heterocyclic compound | ASAHI KASEI PHARMA CORP | 2011-06-08 | — | — | CN | disclosed |
| EP-2298767-A1 | NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TRPA1 1229/4885MAP2K4 793/4885MAPK1 192/4885 |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, EDNRA, NMUR1 | TRPA1 232/4885MAP2K4 2533/4885MAPK1 178/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | TRPA1 4079/4885MAP2K4 772/4885MAPK1 233/4885 |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, TNNI3K, CILK1 | TRPA1 4655/4885MAP2K4 566/4885MAPK1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.